Evaluation and monitoring of isotretinoin use in Iran

Archives of Iranian Medicine

Volumn 15, Issue 7, 2012, Pages 409-412

  Entezari Maleki, Taher ^a,b   Hadjibabaie, Molouk ^a   Dousti, Samaneh ^b   Salamzadeh, Jamshid ^c   Hayatshahi, Alireza ^a   Javadi, Mohammad Reza ^a   Gholami, Kheirollah ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN;

ACNE; ADOLESCENT; ADULT; ARTICLE; CONTRACEPTION; DRUG EFFICACY; DRUG INDICATION; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; FEMALE; HUMAN; INAPPROPRIATE PRESCRIBING; IRAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCRIPTION; PROSPECTIVE STUDY; RECURRENCE RISK; TERATOGENICITY; TREATMENT DURATION;

ADOLESCENT; ADULT; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; IRAN; ISOTRETINOIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84865655790     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Kraning KK, Odland GF. Prevalence, morbidity, and cost of dermatological diseases. J Invest Dermatol 1979; 73: 395-401.
2. White GM. Recent findings in the epidemiologic evidence, classification, and subtypes ofacne vulgaris. J Am Aead Dermatol.1998; 39(suppl 2): 34.
3. Thomas DR. Psychosocial effects of acne. J Cutan Med Surg. 2004; 8 (suppl 4): 3-5.
4. Koo J. The psychosocial impact of acne: patients' perceptions. J Am Acad Dermatol. 1995; 32: 26-30.
5. Fried RG, Wechsler A. Psychological problems in the acne patients. Dermatol Ther. 2006; 19: 237-240.
6. Brown SK, Shalita AR. Acne vulgaris. Lancet. 1998 20; 351: 1871-1876.
7. Brecher AR, Orlow SJ. Oral retinoid therapy for dermatological conditions in children and adolescents. J Am Acad Dermatol. 2003; 49: 171-182.
8. Ellis CN, Krach KJ. Uses and complications of Isotretinoin therapy. J Am Acad Dermatol. 2001; 45(5): 150-157.
9. Johnson BA, Nunley JR. Use of systemic agents in the treatment of acne vulgaris. Am Fam Physician. 2000; 62:1823-1836.
10. Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, Braun JT, et al. Retinoic acid embryopathy. N Engl J Med. 1985; 313: 837-841.
11. Mitchell AA, Van Bennekom CM, Louik C. A pregnancy-prevention program in women of childbearing age receiving Isotretinoin. N Engl J Med. 1995; 333: 101-106.
12. Hull PR, Demkiw-Bartel C. Isotretinoin use in acne: prospective evaluation of adverse events. J Cutan Med Surg. 2000; 4: 66-70.
13. Wysowski DK, Pitts M, Beitz J. An analysis of reports of depression and suicide in patients treated with isotretinoin. J Am Acad Dermatol. 2001; 45: 515-519.
14. Scheinman PL, Peck GL, Rubinow DR, Di Giovanna JJ, Abangan DL, Ravin PD. Acute depression from isotretinoin [letter]. J Am Acad Dermatol. 1990; 22: 1112-1114.
15. Health Ministry of Iran. The Annual Report of Drugs Prescriptions 2001-2007.
16. Wysowski DK, Swann J, Vega A. Use of isotretinoin (Accutane) in the United States: Rapid increase from 1992 through 2000. J Am Acad Dermatol. 2002; 46: 505-509.
17. Stern RS. Acne therapy: Medication use and sources of care in officebased practice. Arch Dermatol. 1996; 132: 776-780.
18. Stern RS. The prevalence of acne on the basis of physical examination. J Am Acad Dermatol. 1992; 26: 931-935.
19. Hanson N, Leachman S. Safety Issues in Isotretinoin therapy. Semin Cutan Med Surg. 2001; 20: 166-183.
20. Katsambas A, Papakonstantinou A. Acne: systemic treatment. Clin I Dermatol. 2004; 22: 412-418.
21. Leyden JJ. The role of isotretinoin in treatment of acne: personal observations. J Am Acad Dermatol. 1998; 39: 45-49.